Clinical Trial

PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer

Recruiting
View on ClinicalTrials.gov →
Summary
The objective of this study was to investigate the feasibility of a PD-1 inhibitor in combination with progesterone as a means of preserving fertility in patients with early-stage mismatch repair-deficient (MMRd) endometrial cancer who wish to preserve fertility.
Protocol Amendment History 1 change
critical Recruitment opened 2026-08-11
Trial Details
NCT Number NCT06549855
Lead Sponsor Peking University People's Hospital
Collaborators: Peking Union Medical College Hospital, Peking University Third Hospital, Huazhong University of Science and Technology, Tianjin Medical University, Shandong University, Shengjing Hospital, Beijing Chao Yang Hospital
Conditions Endometrial Cancer, Endometrioid Carcinoma, Mismatch Repair Deficiency
Enrollment 10 participants
Start Date 2024-09-02
Primary Completion 2029-07 (estimated)
Study Completion 2029-10 (estimated)
Updated on ClinicalTrials.gov 2026-08-10